Edick Paul R 4
4 · Xeris Biopharma Holdings, Inc. · Filed Nov 12, 2021
Insider Transaction Report
Form 4
Edick Paul R
DirectorSee Remarks
Transactions
- Purchase
Common Stock
2021-11-11$2.08/sh+200,000$415,760→ 808,064 total
Holdings
- 13,430(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.97 to $2.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F2]The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.